Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
Abstract
Objective:To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS).
Methods:Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed.
Results:Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye.
Conclusions:A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.
Research topics
Related publications
View all publications- BMC Neuroscience2099 Dec 31
- Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21.J Neurol Neurosurg Psychiatry. 2015 Sep 29. pii: jnnp-2015-311486. doi: 10.1136/jnnp-2015-311486.2015 Sep 29
- Arch Neurol. 2009 Jan;66(1):125-9. doi: 10.1001/archneurol.2008.517. Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms: an amygdaloid variant of Alzheimer disease. Kile SJ1, Ellis WG, Olichney JM, Farias S, DeCarli C. Author information 1Department of Neurology, University of California at DavisArch Neurol. 2009 Jan;2009 Jan 20